Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jfo.2017.10.015 | DOI Listing |
Ocul Immunol Inflamm
November 2024
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Purpose: To report a case of cytomegalovirus (CMV)-related hemorrhagic retinal vasculitis in a patient with multiple myeloma (MM) on daratumumab, a trial cereblon E3 ligase modulatory drug (CELMoD), dexamethasone, and acyclovir, and discuss clinical implications for CMV prophylaxis.
Methods: Case report, narrative review of CMV reactivation risk in MM patients on daratumumab and antiviral agent efficacy for CMV prophylaxis.
Results: A 63-year-old female presented with 3 days of progressive unilateral vision loss in the right eye to the level of counting fingers.
Medicine (Baltimore)
September 2024
Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan.
Rationale: The prevalence of idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome is <1/1,000,000, and it tends to occur in young women. Panretinal photocoagulation, focal laser photocoagulation, peripheral cryopexy, vitrectomy, and corticosteroid therapy are the traditional treatments. We reported a case of a senile patient with IRVAN syndrome who presented with severe exudation in both eyes and macular edema in the left eye, successfully treated by serial intravitreal aflibercept injections.
View Article and Find Full Text PDFJ Yeungnam Med Sci
October 2024
Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Korea.
Ocul Immunol Inflamm
December 2024
Department of Ophthalmology, Pusan National University School of Medicine, Yangsan, South Korea.
Purpose: To report a case of bilateral retinal vasculitis in a patient with non-small cell lung cancer undergoing treatment with osimertinib.
Case Report: A 58-year-old woman with lung adenocarcinoma (T4N3M1a stage IV) presented with blurry vision in both eyes (OU). Eighteen months before symptom onset, the treatment was changed from afatinib (20 mg/day) to osimertinib (80 mg/day) because of tumor progression.
Ocul Immunol Inflamm
June 2024
Department of Ophthalmology, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!